Evan David Seigerman, BMO managing director, joins Fast Money to discuss Novo sinking on its obesity drug data.







BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints [F6Pgb31E1vT]

BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints [F6Pgb31E1vT]

| 1h 28m 28s | Video has closed captioning.

Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data. #when to take the keto gummies #diet pills men

Aired: December 22, 2024

Rating: TV-14

Buy Now:

Problems Playing Video? | Closed Captioning

Related to This Episode

  • Q&A with Heidi Thomas

    Q&A with Heidi Thomas

    Writer & Executive Producer of BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints [F6Pgb31E1vT] on the secret of the show.

  • Relive the Drama with Gif Recaps

    Relive the Drama with Gif Recaps

    Miss an episode? Catch up on all things Poplar with our gif recaps.

  • Visit the Official Site

    Visit the Official Site

    Dive deeper into BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints [F6Pgb31E1vT] with cast Q&As, expert blogs, BTS photos, and more!

  • Explore the Modern Midwives Blog

    Explore the Modern Midwives Blog

    Experienced midwives discuss how BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints [F6Pgb31E1vT] intersects with modern day Midwifery.

Learn About Midwifery Today

Blog

Learn About Midwifery Today

Read the Modern Day Midwives Blog and learn more about our bloggers, all experienced midwives.

Read now